Clinical Trials Browser

Completed × INDUSTRY × Immune Checkpoint Inhibitors × Clear all

NCT02973789 2026-03-18

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Phase 3 Completed

291 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT04417465 2025-09-25

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03425279 2025-09-23

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Phase 1/2 Completed

Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT05509699 2025-08-29

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Phase 2 Completed

Small Cell Lung Carcinoma

NCT03504488 2025-01-15

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Phase 1/2 Completed

BreastDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Triple Negative Breast Neoplasms

NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Phase 1/2 Completed

40 enrolled 16 charts

Other solid neoplasm

Solid Tumor, Adult

NCT04721223 2024-09-19

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03790488 2023-07-03

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

Phase 1 Completed

Neoplasms

NCT02574533 2017-09-27

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

Phase 1 Completed

Melanoma